NASDAQ:IPSC

Century Therapeutics (IPSC) Stock Forecast, Price & News

$2.85

-0.05 (-1.72%)

(As of 08/9/2023 ET)

Compare

Today's Range: $2.82
▼
$2.89
50-Day Range: $2.84
▼
$3.53
52-Week Range: $2.81
▼
$12.87

Volume: 60,043 shs
Average Volume: 142,693 shs
Market Capitalization: $169.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.63

Century Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 518.4% Upside
$17.63 Price Target
Short Interest: Healthy
3.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.20
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.07) to ($1.95) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

562nd out of 969 stocks

Biological Products, Except Diagnostic Industry

92nd out of 164 stocks

3.5

Analyst's Opinion

Consensus Rating
Century Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.63, Century Therapeutics has a forecasted upside of 518.4% from its current price of $2.85.
Amount of Analyst Coverage
Century Therapeutics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.49% of the float of Century Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Century Therapeutics has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in Century Therapeutics has recently decreased by 22.40%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Century Therapeutics does not currently pay a dividend.
Dividend Growth
Century Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IPSC.

2.3

News and Social Media Coverage

News Sentiment
Century Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Century Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Century Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.60% of the stock of Century Therapeutics is held by insiders.
Percentage Held by Institutions
Only 33.57% of the stock of Century Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Century Therapeutics are expected to grow in the coming year, from ($2.07) to ($1.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Century Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Century Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Century Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

IPSC Price History

30 days | 90 days | 365 days | Advanced Chart

IPSC Stock News Headlines

August 9, 2023 | finanznachrichten.de

Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 9, 2023 | finance.yahoo.com

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

August 9, 2023 | finance.yahoo.com

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates

August 1, 2023 | finance.yahoo.com

Century Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year ago

May 12, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Century Therapeutics (IPSC)

May 12, 2023 | finance.yahoo.com

Century Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

May 11, 2023 | msn.com

Century Therapeutics: Q1 Earnings Insights

August 10, 2023 | Chaikin Analytics (Ad)

Man Behind Wall Street AI Issues Urgent BUY

It flashed bullish on all 10 of the top 10 stocks of 2022 – detecting rare 100% winners during the worst year for stocks since 2008. Here’s its top pick for 2023 (name and ticker).

May 11, 2023 | finanznachrichten.de

Century Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023 | finance.yahoo.com

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates

May 11, 2023 | finance.yahoo.com

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

April 17, 2023 | benzinga.com

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

April 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Century Therapeutics (IPSC) Buy Recommendation

April 13, 2023 | markets.businessinsider.com

Analyst Ratings for Century Therapeutics

April 13, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY) and Century Therapeutics (IPSC)

April 12, 2023 | msn.com

Century Therapeutics CEO Lalo Flores steps down, Greg Russotti appointed as ad-interim Chief Executive Officer

April 12, 2023 | bizjournals.com

Century Therapeutics CEO departs amid shakeup in C-suite

April 12, 2023 | finance.yahoo.com

Century Therapeutics Announces Leadership Changes

March 21, 2023 | markets.businessinsider.com

Chardan Capital Sticks to Their Buy Rating for Century Therapeutics (IPSC)

March 20, 2023 | msn.com

Century Therapeutics's Return On Capital Employed Overview

March 16, 2023 | markets.businessinsider.com

EF Hutton Sticks to Their Buy Rating for Century Therapeutics (IPSC)

March 16, 2023 | finanznachrichten.de

Century Therapeutics, Inc.: Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

March 16, 2023 | msn.com

Century Therapeutics GAAP EPS of -$2.27 beats by $0.05, revenue of $5.2M misses by $1.76M

March 16, 2023 | markets.businessinsider.com

Where Century Therapeutics Stands With Analysts

March 16, 2023 | finance.yahoo.com

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

March 16, 2023 | finance.yahoo.com

Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

See More Headlines

Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IPSC Company Calendar

Last Earnings: 5/11/2023
Today: 8/09/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IPSC
CUSIP: N/A
CIK: 1850119
Web: www.centurytx.com
Phone: 267-817-5790
Fax: N/A
Employees: 163
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.63
High Stock Price Forecast: $28.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +527.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-130,930,000.00
Net Margins: -2,127.33%
Pretax Margin: -2,105.44%
Return on Equity: -39.33%
Return on Assets: -25.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.24
Quick Ratio: 9.24

Sales & Book Value

Annual Sales: $5.20 million
Price / Sales: 32.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.13 per share
Price / Book: 0.56

Miscellaneous

Outstanding Shares: 59,580,000
Free Float: 55,053,000
Market Cap: $169.80 million
Optionable: Not Optionable
Beta: 0.63

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Michael C. Diem M.D. (Age 52)
Chief Financial Officer
Comp: $650.66k

Dr. Adrienne Farid Ph.D. (Age 61)
COO & Head of Early Devel.
Comp: $650.66k

Dr. Gregory Russotti Ph.D. (Age 56)
Interim Pres & CEO

Dr. Luis Borges (Age 61)
Chief Scientific Officer

Mr. Kenneth J. Dow J.D.
Sr. VP of Gen. Counsel

Dr. Shane Williams Ph.D.
Chief People Officer

Dr. Hyam I. Levitsky M.D. (Age 65)
Pres of R&D

Michael Naso Ph.D.
Sr. VP of Cell Engineering

Mr. Douglas Carr CPA
Sr. VP of Fin. & Operations and Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IPSC Stock - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPSC shares.
View IPSC analyst ratings or view top-rated stocks.
What is Century Therapeutics' stock price forecast for 2023?: 7 Wall Street research analysts have issued 1 year price targets for Century Therapeutics' stock. Their IPSC share price forecasts range from $14.00 to $28.00. On average, they predict the company's share price to reach $17.63 in the next year. This suggests a possible upside of 518.4% from the stock's current price.
View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts.
How have IPSC shares performed in 2023?: Century Therapeutics' stock was trading at $5.13 at the start of the year. Since then, IPSC stock has decreased by 44.4% and is now trading at $2.85.
View the best growth stocks for 2023 here.
When is Century Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our IPSC earnings forecast.
How were Century Therapeutics' earnings last quarter?: Century Therapeutics, Inc. (NASDAQ:IPSC) issued its earnings results on Thursday, May, 11th. The company reported ($0.53) EPS for the quarter, hitting the consensus estimate of ($0.53). The business earned $1.72 million during the quarter, compared to analyst estimates of $2.26 million. Century Therapeutics had a negative trailing twelve-month return on equity of 39.33% and a negative net margin of 2,127.33%.
When did Century Therapeutics IPO?: (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Century Therapeutics' stock symbol?: Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."
Who are Century Therapeutics' major shareholders?: Century Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include New York Life Investment Management LLC (0.20%), Bank of New York Mellon Corp (0.13%) and Acadian Asset Management LLC (0.08%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L.
View institutional ownership trends.
How do I buy shares of Century Therapeutics?: Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Century Therapeutics' stock price today?: One share of IPSC stock can currently be purchased for approximately $2.85.
How much money does Century Therapeutics make?: Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $169.80 million and generates $5.20 million in revenue each year. The company earns $-130,930,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.
How many employees does Century Therapeutics have?: The company employs 163 workers across the globe.
How can I contact Century Therapeutics?: The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com.

This page (NASDAQ:IPSC) was last updated on 8/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial